RxDoctor Payments Data

Amelia Bitonte, DO

Internal Medicine · Akron, OHNPI 1942696547

Payments from drug & device makers

$277in general payments, 2019–2025

Across 10 payments — averaging $27.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$146
  • Merck$36
  • Daiichi Sankyo Inc.$30
  • Mannkind Corporation$14
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$14
  • Amarin Pharma, Inc.$13
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$277100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$277 in reported general payments places this provider in the 55th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$56,677
Medicare patients
151
Services billed
890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$67,205
JardianceEmpagliflozin52$42,656
JanuviaSitagliptin Phosphate39$36,914
XareltoRivaroxaban34$32,271
TrulicityDulaglutide25$26,698
OzempicSemaglutide22$22,853
MyrbetriqMirabegron16$12,928
EntrestoSacubitril/Valsartan17$12,519
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$11,899
SymbicortBudesonide/Formoterol Fumarate21$8,186
LinzessLinaclotide12$6,532
Atorvastatin Calcium531$5,787
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$4,219
Metoprolol Succinate275$4,143
Losartan Potassium310$3,897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$36$36,91439 claims
AstraZenecaSymbicort$13$8,18621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →